TY - JOUR T1 - Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis JF - medRxiv DO - 10.1101/2021.10.11.21264694 SP - 2021.10.11.21264694 AU - Tatjana Schwarz AU - Carolin Otto AU - Terry C. Jones AU - Florence Pache AU - Patrick Schindler AU - Moritz Niederschweiberer AU - Felix A. Schmidt AU - Christian Drosten AU - Victor M. Corman AU - Klemens Ruprecht Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/22/2021.10.11.21264694.abstract N2 - Objective To analyze humoral and cellular immune responses to SARS-CoV-2 vaccinations and infections in anti-CD20 treated patients with multiple sclerosis (pwMS).Methods 181 pwMS on anti-CD20 therapy and 41 pwMS who began anti-CD20 therapy were included in a prospective, observational, single-center cohort study between March 2020 and August 2021. 51 pwMS under anti-CD20 treatment, 14 anti-CD20 therapy-naïve pwMS and 19 healthy controls (HC) were vaccinated twice against SARS-CoV-2. We measured SARS-CoV-2 spike protein (full-length, S1 domain and receptor binding domain) immunoglobulin (Ig)G and S1 IgA and virus neutralizing capacity and avidity of SARS-CoV-2 antibodies. SARS-CoV-2 specific T cells were determined by interferon-γ release assays.Results Following two SARS-CoV-2 vaccinations, levels of IgG and IgA antibodies to SARS-CoV-2 spike protein as well as neutralizing capacity and avidity of SARS-CoV-2 IgG were lower in anti-CD20 treated pwMS than in anti-CD20 therapy-naïve pwMS and in HC (p<0.003 for all pairwise comparisons). However, in all anti-CD20 treated pwMS vaccinated twice (n=26) or infected with SARS-CoV-2 (n=2), in whom SARS-CoV-2 specific T cells could be measured, SARS-CoV-2 specific T cells were detectable, at levels similar to those of twice-vaccinated anti-CD20 therapy-naïve pwMS (n=7) and HC (n=19). SARS-CoV-2 S1 IgG levels (r=0.42, p=0.002), antibody avidity (r=0.7, p<0.001) and neutralizing capacity (r=0.44, p=0.03) increased with time between anti-CD20 infusion and second vaccination. Based on detection of SARS-CoV-2 antibodies, SARS-CoV-2 infections occurred in 4/175 (2.3%) anti-CD20 treated pwMS, all of whom recovered fully.Interpretation These findings should inform treatment decisions and SARS-CoV-2 vaccination management in pwMS.Competing Interest StatementV.M.C. is named together with Euroimmun GmbH on a patent application filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing. K.R. is site principal investigator in clinical trials sponsored by Roche, the manufacturer of ocrelizumab and rituximab, and received research support from Novartis Pharma, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charite and Arthur Arnstein Foundation, and travel grants from Guthy Jackson Charitable Foundation.Funding StatementParts of this work were supported by grants from the Berlin Institute of Health (BIH) and Berlin University Alliance to CD and VMC. This study was further supported by the German Ministry of Education and Research through Forschungsnetzwerk der Universitaetsmedizin zu COVID-19, COVIM, FKZ: 01KX2021 to CD and VMC, and projects VARIPath (01KI2021) to VMC. VMC is a participant in the BIH-Charite Clinician Scientist Program funded by Charite - Universitaetsmedizin Berlin and the Berlin Institute of Health. KR is a participant in the BIH Clinical Fellow Program funded by Stiftung Charite. FP is a participant in the BIH-Charite Clinician Scientist Program funded by Charite - Universitaetsmedizin Berlin and the Berlin Institute of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethical committee of Charite - Universitaetsmedizin Berlin (EA2/152/21 and EA1/068/20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are contained in the manuscrip or are available upon reasonable request to the authors. ER -